19.59
前日終値:
$19.58
開ける:
$19.57
24時間の取引高:
421.02K
Relative Volume:
0.43
時価総額:
$622.57M
収益:
$17.16M
当期純損益:
$-163.62M
株価収益率:
-3.222
EPS:
-6.08
ネットキャッシュフロー:
$-121.61M
1週間 パフォーマンス:
-7.55%
1か月 パフォーマンス:
+15.92%
6か月 パフォーマンス:
-8.07%
1年 パフォーマンス:
-25.31%
Anaptysbio Inc Stock (ANAB) Company Profile
名前
Anaptysbio Inc
セクター
電話
858-362-6295
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ANAB
Anaptysbio Inc
|
19.59 | 622.57M | 17.16M | -163.62M | -121.61M | -6.08 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-04 | 開始されました | Wolfe Research | Outperform |
2024-12-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2024-12-02 | ダウングレード | BTIG Research | Buy → Neutral |
2024-07-22 | 開始されました | H.C. Wainwright | Buy |
2024-07-19 | アップグレード | JP Morgan | Neutral → Overweight |
2024-04-16 | 開始されました | Leerink Partners | Outperform |
2024-04-11 | 開始されました | Wells Fargo | Overweight |
2024-03-12 | アップグレード | Wedbush | Neutral → Outperform |
2024-02-26 | 開始されました | BTIG Research | Buy |
2024-02-21 | 開始されました | Stifel | Buy |
2024-02-16 | 開始されました | Piper Sandler | Overweight |
2023-05-22 | アップグレード | JP Morgan | Underweight → Neutral |
2023-05-18 | 開始されました | TD Cowen | Outperform |
2023-01-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2022-11-01 | アップグレード | Guggenheim | Neutral → Buy |
2022-09-19 | 再開されました | H.C. Wainwright | Buy |
2022-09-13 | ダウングレード | Truist | Buy → Hold |
2022-09-01 | 開始されました | Raymond James | Outperform |
2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
2021-06-22 | 開始されました | H.C. Wainwright | Buy |
2021-05-21 | 開始されました | UBS | Neutral |
2021-03-16 | アップグレード | Truist | Hold → Buy |
2021-03-09 | ダウングレード | Wedbush | Outperform → Neutral |
2021-03-08 | ダウングレード | JP Morgan | Overweight → Underweight |
2021-02-11 | アップグレード | JP Morgan | Underweight → Overweight |
2020-10-27 | アップグレード | Wedbush | Neutral → Outperform |
2020-10-14 | アップグレード | Guggenheim | Neutral → Buy |
2019-11-08 | ダウングレード | JP Morgan | Overweight → Underweight |
2019-11-08 | ダウングレード | Jefferies | Buy → Hold |
2019-11-08 | ダウングレード | SunTrust | Buy → Hold |
2019-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
2019-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
2019-06-21 | ダウングレード | Stifel | Buy → Hold |
2018-12-20 | 開始されました | H.C. Wainwright | Buy |
2018-11-21 | 開始されました | JP Morgan | Overweight |
2018-07-19 | 開始されました | Credit Suisse | Outperform |
2018-04-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2018-03-27 | 繰り返されました | Stifel | Buy |
2018-03-06 | 繰り返されました | Stifel | Buy |
2018-02-15 | 繰り返されました | SunTrust | Buy |
2018-01-23 | 繰り返されました | Credit Suisse | Outperform |
2017-11-15 | 開始されました | SunTrust | Buy |
2017-11-09 | 開始されました | Jefferies | Buy |
2017-10-11 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Anaptysbio Inc (ANAB) 最新ニュース
Susquehanna Fundamental Investments LLC Invests $593,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Invesco Ltd. - MarketBeat
Barclays PLC Buys 39,267 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $54.00 at Guggenheim - MarketBeat
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly? - simplywall.st
AnaptysBio First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Boxer Capital Management LLC Purchases New Shares in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Nebula Research & Development LLC Makes New $231,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (ANAB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
AnaptysBio Inc (ANAB) Q1 2025 Earnings: Revenue Surges to $27.8M - GuruFocus
AnaptysBio Inc (ANAB) Q1 2025 Earnings: Revenue Surges to $27.8M, Beating Estimates; EPS at -$1.28, Slightly Below Expectations - GuruFocus
Forecasting The Future: 6 Analyst Projections For AnaptysBio - Benzinga
AnaptysBio (ANAB) Price Target Raised by Guggenheim | ANAB Stock News - GuruFocus
AnaptysBio (ANAB) Price Target Increased Amid Promising Clinical Developments | ANAB Stock News - GuruFocus
AnaptysBio, Inc. (ANAB) Tops Q1 EPS by 2c - StreetInsider
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Q1 Performance | ANAB Stock News - GuruFocus
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update | ANAB Stock News - GuruFocus
ANAPTYSBIO, INC SEC 10-Q Report - TradingView
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
BRIEF-AnaptysBio Q1 Net Income USD -39.329 Million - TradingView
Anaptys Breakthrough: Rosnilimab Shows Strong Phase 2b Results in RA, Multiple Pipeline Catalysts Ahead - Stock Titan
First Light Asset Management LLC Has $11.50 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Wedbush Reaffirms “Outperform” Rating for AnaptysBio (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Geode Capital Management LLC - MarketBeat
JPMorgan Chase & Co. Has $1.52 Million Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Gears Up For Key Trial Readouts In Rheumatoid Arthritis And Lung Cancer - RTTNews
AnaptysBio (ANAB) Stock Maintains Outperform Rating with $40 Pri - GuruFocus
AnaptysBio (ANAB) Stock Maintains Outperform Rating with $40 Price Target | ANAB Stock News - GuruFocus
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
What is the investor’s view on AnaptysBio Inc (ANAB)? - uspostnews.com
A company insider recently bought 65,184 shares of AnaptysBio Inc [ANAB]. Should You Buy? - knoxdaily.com
AnaptysBio (NASDAQ:ANAB) versus Endonovo Therapeutics (OTCMKTS:ENDVD) Head-To-Head Comparison - Defense World
(ANAB) Investment Analysis and Advice - news.stocktradersdaily.com
Investor’s Delight: AnaptysBio Inc (ANAB) Closes Weak at 18.59, Down -1.90 - DWinneX
Gaining Ground: AnaptysBio Inc (ANAB) Closes Lower at 16.34, Down -0.37 - DWinneX
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Russell Investments Group Ltd. - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Raises Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
XTX Topco Ltd Buys 19,727 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Inc (ANAB) Stock: A Comprehensive 52-Week Review - investchronicle.com
What was AnaptysBio Inc (ANAB)’s performance in the last session? - uspostnews.com
Gaining Ground: AnaptysBio Inc (ANAB) Closes Lower at 20.42, Down -5.38 - DWinneX
ANAB Stock Sees Surge of Approximately 12.82% in Last Five Days - knoxdaily.com
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc. - MarketBeat
Anaptysbio Inc (ANAB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):